Human Cell-Based *in vitro* Phenotypic Profiling for Drug Safety-Related Attrition

Ellen L. Berg*

Eurofins Discovery, Translational Biology, Burlingame, CA, United States

Ensuring the safety of new drugs is critically important to regulators, pharmaceutical researchers and patients alike. Even so, unexpected toxicities still account for 20–30% of clinical trial failures, in part due to the persistence of animal testing as the primary approach for de-risking new drugs. Clearly, improved methods for safety attrition that incorporate human-relevant biology are needed. This recognition has spurred interest in non-animal alternatives or new approach methodologies (NAMs) including *in vitro* models that utilize advances in the culture of human cell types to provide greater clinical relevance for assessing risk. These phenotypic assay systems use human primary and induced pluripotent stem cell-derived cells in various formats, including co-cultures and advanced cellular systems such as organoids, bioprinted tissues, and organs-on-a-chip. Despite the promise of these human-based phenotypic approaches, adoption of these platforms into drug discovery programs for reducing safety-related attrition has been slow. Here we discuss the value of large-scale human cell-based phenotypic profiling for incorporating human-specific biology into the de-risking process. We describe learnings from our experiences with human primary cell-based assays and analysis of clinically relevant reference datasets in developing *in vitro*-based toxicity signatures. We also describe how Adverse Outcome Pathway (AOP) frameworks can be used to integrate results from diverse platforms congruent with weight-of-evidence approaches from risk assessment to improve safety-related decisions in early discovery.

**Keywords:** drug discovery, phenotypic assays, toxicity mechanism, reference database, data mining, toxicity testing, new approach methodologies

**INTRODUCTION**

The use of “omics” profiling technologies (genomics, proteomics, metabolomics, etc.) and *in vitro* methods in discovery toxicology has exploded in recent years and begun to advance our understanding of toxicity mechanisms (Beilmann et al., 2019; Thomas et al., 2019). The field is still young, however, as the molecular mechanisms underlying most human toxicities remain unknown. Despite this, identified mechanisms reveal critical differences between humans and animals commonly employed in safety tests (Jang et al., 2019). In addition to the well-appreciated differences in gene and protein sequences, important influences of lifespan, environment, and physical architecture on toxicity mechanisms are less often recognized and addressed.
Lifespan: Whereas humans live for many decades (~70 years), rodents are short lived (~2 years) with comparatively limited regulatory mechanisms supporting genome maintenance and integrity. Indeed, DNA mutation rates are higher in mice than humans (Milholland et al., 2017) and expression of DNA repair genes is lower (MacRae et al., 2015). Humans also appear to be more reliant on immune system surveillance to identify and eliminate cells containing genomic mutations (Corthay, 2014). These lifespan-related differences in DNA damage response mechanisms are important to consider when assessing the relevance of resource-intense and costly two-year animal carcinogenicity studies, often performed for new product regulatory submissions (Corvi et al., 2017).

Environment: Environmental factors contribute to the many differences in immune system function described between humans and research animals (Mestas and Hughes, 2004; Seok et al., 2013). Humans live in the open world exposed to a diverse array of chemical, microbial, and infectious stressors over an extended timeframe. In contrast, research animals are housed in small groups in highly standardized, clean facilities with filtered water and specialized food. Indeed, immune mechanisms appear to drive a significant fraction of human-specific toxicity susceptibility and are associated with increased risk of adverse effects to drug exposure, including idiosyncratic liver toxicity (Godoy et al., 2013). Cytokine release syndrome, the tragic outcome in 2006 of the Phase I clinical trial of the CD28 super-agonist antibody TGN 1412, was an unpredicted immune-system toxicity in humans not observed in preclinical testing (Lee et al., 2014).

Physical Architecture: Toxicities are also influenced by species-specific tissue and organ architecture—for example the vascular system. Vascular beds in rodents are densely arranged, with characteristically short distances between the average tissue resident cell and the closest blood vessel (Karbowiski, 2011; Brissova et al., 2015). In contrast, the vasculature in human tissues is less dense and contains larger vessels that are subject to significantly higher vascular wall shear stresses. Humans are more vulnerable than rodents to blocks in blood vessel flow (heart attacks, pulmonary thrombosis, stroke) and as a consequence, manifest additional regulatory mechanisms to control hemostasis. Dogs, with a higher degree of similarity to humans with regard to cardiovascular system architecture, are often employed in cardiovascular toxicity studies. These costly studies, however, have had limited impact on reducing safety attrition. Cardiovascular system-related toxicities continue to be one of the leading causes of clinical failures (Cook et al., 2014), emphasizing a critical need for NAMs that reflect human-specific vulnerabilities.

Translational approaches that capture the biology and mechanisms relevant to cell proliferation, immune, and inflammatory responses and vascular biology are well placed to reveal human-specific toxicity impacts. For these data to be utilized effectively, organizational strategies that integrate data from multiple platforms and capture mechanistic relationships are needed. This in turn can expedite adoption of human-based in vitro assays for safety de-risking in discovery.

ADVERSE OUTCOME PATHWAY FRAMEWORKS FOR INTEGRATING ASSAY PLATFORM RESULTS

The Adverse Outcome Pathway (AOP) approach provides a particularly useful framework as it aligns platforms and data types to key mechanistic steps. The use of AOPs to organize knowledge in support of toxicity risk assessments has been advanced by the OECD and the US EPA (Edwards et al., 2016; https://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-screening-and-toxicogenomics.htm). AOPs are applied in a weight-of-evidence approach for risk assessment and used to connect molecular initiating events (e.g., target interactions) to adverse outcomes through a series of key events at distinct levels of the biological hierarchy: pathway, tissue, organ, organism, population. Figure 1 shows how the AOP framework can be used to integrate data from target-based platforms, phenotypic assays, more advanced complex systems, and clinical studies. Assay platforms map to different elements of the AOP framework, with important advantages and disadvantages of each approach indicated.

Target-based profiling platforms map to the first step in the AOP, the molecular initiating event (MIE). Broad profiling across diverse targets is a long-established approach for de-risking lead compounds (Bowes et al., 2012). Key advantages of target-based profiling include inclusion for testing large numbers of compounds and statistical robustness of the resulting data, enabling quantitative differentiation of close analogs. Assays tend to be simple and fast with comparatively limited numbers of experimental variables. The disadvantages of target-based profiling include the limited numbers of targets available, restrictions on modes of action covered (e.g., some platforms do not differentiate between activators and inhibitors, or capture allosteric mechanisms), and potential for assay interference (i.e., frequent hitters, fluorescent compounds). Most importantly, target-based platforms simply do not capture many of the regulatory mechanisms controlling the outcome of drug-target interactions in vivo, such as pathway feedback mechanisms or processes that dictate drug concentration and localization in target tissues (e.g., ADME properties of absorption, deposition, metabolism and excretion).

Standard cell-based (e.g., 2D) assays map to the next step of the AOP framework, the pathway level. These assays capture some mechanisms relevant to in vivo activity including cell uptake and the ability to assess target function in the presence of intracellular pathway feedback mechanisms, depending on culture conditions. Feedback mechanisms relevant to human responses are preferentially retained by human primary or stem-cell-derived cells. These cell types more closely reflect cell behaviors in human tissues than do immortalized cell lines. Phenotypic 2D assays are scalable, with moderate to high throughput, and can achieve reasonably good statistical performance. These features are key for
### ADVERSE OUTCOME PATHWAY FRAMEWORK

| Target-Based Assays | Pathway | Tissue | Organ | Patient |
|---------------------|---------|--------|-------|---------|
| Molecular initiating Event | Key Event | Co-Cultures, Organoids, Bioprinted Tissues | Tissue Chips (Organs-on-a-chip) | Outcome |
| Standard Cell-Based 2D Assays | Key Event | | |

**Phenotypic Assays / Systems**

### ASSAY PLATFORMS: ADVANTAGES & DISADVANTAGES

| Target-Based Assays | 2D | Phenotypic Assays | 3D | Tissue Chips (Organs-on-a-Chip) |
|---------------------|----|-------------------|----|---------------------------------|
| Human Cell Lines | Human Primary Cells | iPSC-Derived Cells | Organoids | Bioprinted Tissues |
| Assays capture target engagement | High throughput | Highest physiological relevance | Access to cell types not available as primary cells | 3D architecture provides enhanced physiological relevance | Capture tissue/organ level functions |
| High throughput, fast | Assays capture cell uptake mechanisms | Assays capture pathway feedback mechanisms | Genetic modification | Tissue-like organization of cell types provides enhanced physiological relevance | Incorporate metabolic competence |
| High statistical performance (high reproducibility, low variability) | Reference database | Reference database | Extended culture possible | Extended culture possible | Extended culture possible |
| Reference database | | | | |
| Assays do not capture drug localization mechanisms | Cells are immortalized | Limitations on cell numbers | Costly to generate cell numbers for large scale screening | No reference database | Low throughput |
| Abnormal pathway feedback mechanisms | Potential for variation from donor to donor | Difficult to achieve fully adult phenotypes | | | Costly |
| Assays do not capture pathway feedback mechanisms | | | | | High variability |
| | | | | | No reference database |
| | | | | | |
| Key Advantages | | | | | |
| Key Disadvantages | | | | | |
| Comments | | | | | |

**FIGURE 1** Mapping assay platforms to the Adverse Outcome Pathway framework.
development of reference databases and analytical tools to run the comparative analyses that provide important mechanistic interpretation of phenotypic assay results. Disadvantages of 2D format assays include limited culture periods and lack of physiologically relevant 3D architecture and competence for drug metabolism. Past efforts have used individual organ-specific cell types (e.g., cardiomyocytes or hepatocytes) to predict organ-specific toxicity, with cell function or cytotoxicity as proxy endpoints (Godoy et al., 2013; Dragovic et al., 2016; Magdy et al., 2018). The performance of these assays in predicting organ-specific toxicity (hepatocytes for liver toxicity; cardiomyocytes for cardiovascular system toxicity) has been unsatisfactory as organ toxicity can be caused by a number of mechanisms involving additional cell types, such as immune cells or the vasculature. Limited performance of these assays (Dragovic et al., 2016) has led researchers toward more advanced cellular systems that incorporate diverse cell types and capture complex aspects of tissue and organ-level biology.

Organoids, bioprinted tissues, and organs-on-a-chip represent advanced cellular systems that incorporate additional physiologically relevant features such as 3D architecture, metabolic competence, and tissue level functions (Horvath et al., 2016). The key advantage of these platforms is the ability to reflect higher level tissue functions, including drug metabolism and its impacts. Therefore, these approaches map to the tissue and organ levels of the AOP (Figure 1). While these systems hold promise in safety de-risking, confidence in their use and adoption into the drug discovery process has lagged, tempered by lack of throughput and limited validation data. Low assay throughputs (whether technical or economical) preclude development of reference standards databases—large scale data sets are needed to truly assess platform robustness, assay reproducibility, and data predictivity. Scale and throughput have advanced somewhat for organoids and 3D cultures with interesting emerging results, albeit with only moderately sized data sets (Sirenko et al., 2019). As the complexity of advanced cellular systems grows with larger numbers of experimental variables and longer culture times, data variability inevitably increases and may become the limiting factor in their utility and adoption. Without capabilities for large scale comparative analyses, these systems and platforms provide limited mechanism of action, so may best support further exploration of well-characterized drug leads already tested for target selectivity in large panels and evaluated for effects on diverse cellular pharmacology.

**PHENOTYPIC PROFILING FOR HUMAN-RELEVANT TOXICITY MECHANISMS**

In isolation, no single phenotypic assay or platform provides sufficient predictive power for safety-related decisions. Integrating information from diverse sources in a weight-of-evidence approach for assessing risk is needed. As touched on above, each assay technology has advantages and disadvantages, including applicability domains, statistical and reproducibility limitations, validation to clinical results, reference database availability for data mining and analytics, and sensitivity to artifacts. However, phenotypic platforms that can connect target mechanisms to tissue context may be preferentially useful.

The BioMAP® platform of human primary cell-based systems (Eurofins Discovery) was successfully used by the EPA for the ToxCast™ program [(Houck et al., 2009; Kleinstreuer et al., 2014a) and data available through the website: https://comptox.epa.gov/dashboard], and by various pharmaceutical researchers for characterization of new drug leads (reviewed in Berg, 2017). Systems of the BioMAP platform represent a broad range of tissue biology (vascular, respiratory, immune, tumor microenvironment and skin) in individual and co-culture formats; protein biomarkers with established clinical annotations serve as measured translational biology endpoints. The platform addresses biology relevant to human-specific toxicity mechanisms and includes proliferation endpoints to enable detection of cell type selective mechanisms, particularly important for assessing the safety of oncology drugs where discrimination between tumor and normal host cells is critical for minimizing adverse effects. Systems covering biology of the vasculature incorporate endothelial cells and vascular smooth muscle cells, and studies using these assays have led to the discovery of a novel toxicity mechanism underlying drug-induced thrombosis related side effects in humans (Berg et al., 2015). Limitations of the BioMAP platform include a lack of 3D architecture, relatively short culture times (1–6 days), and limited capabilities for drug metabolism. Notwithstanding, the format and scale of this platform offers significant advantages over more complex advanced cellular systems. In particular, the level of reproducibility and throughput has provided for generation of a large-scale reference database and development of analytics for assigning mechanism of action (Berg, 2017).

Comprehensive databases, given reasonable levels of assay reproducibility and variability, allow comparative analyses to reference standards and mechanism of action distinctions. The BioMAP Reference Database contains biomarker profiles generated from >4,500 test agents including drugs, experimental chemicals, extracts, and environmental chemicals, enabling mechanism of action classification development of predictive toxicity signatures. Large-scale databases exist for other phenotypic platforms including: the database of drug sensitivities across panels of cancer cell lines (Seashore-Ludlow et al., 2015; and the Cancer Therapeutics Response Portal CTRP, https://portals.broadinstitute.org/ctrp/); the database of gene expression profiles containing a subset of genes using the L1000 platform (Subramanian et al., 2017); the NIH LINCS program portal for Library of Integrated Network-Based Cellular Signatures, http://www.lincsproject.org/LINCS/); and a database of images from high content imaging assays using multiplexed fluorescent dyes (Cell Painting, Bray et al., 2017). Given sufficient data and statistical power, phenotypic assays can distinguish diverse mechanisms of action, with prediction accuracy increasing with increasing size of the database coverage.
DEVELOPMENT OF TOXICITY SIGNATURES

Recently, BioMAP data from drugs and experimental therapies tested in humans has been applied to identify phenotypic signatures (toxicity signatures) associated with particular clinical adverse effects (e.g., Berg et al., 2015; Shah et al., 2017). BioMAP profiles for a small set of key reference drugs associated with a particular clinical adverse effect (AE or adverse outcome) were analyzed to identify shared biomarker activities among drugs associated with the same AE. Common activities were investigated for their potential to contribute to a toxicity

| Toxicity  | Definition | Key reference compounds | Key biomarker | Pathway/Target mechanisms | References |
|-----------|------------|-------------------------|---------------|----------------------------|------------|
| Acute toxicity | Increased risk of death | A23187, monensin, cycloheximide, actinomycin D, digoxin, bortezomib, valinomycin; Classes: cardiac glycosides, alkylating agents, ionophores | Decreased SRB in multiple systems (five biomarkers in signature) | Protein synthesis inhibition, RNA synthesis inhibition, Na+/K+-ATPase dysfunction | Houck et al., 2009; Berg, 2017 |
| Immuno-suppression | Increased risk of infection | Sirolimus, infliximab, cyclopsorine, tacrolimus, mycophenolate, azathioprine | Decreased T cell proliferation in BioMAP SAg system (five biomarkers in signature) | mTOR, calcineurin, JAK, Hsp90, NFAT, DNA proliferation | Berg, 2017 |
| Skin irritation | Irritation of the skin with reddening and itch | Retinoic acid, retinol, vitamin D, ritonavir, imatinib, 2-chloroethyl ethyl sulfide, calcitriol; Classes: retinoids, vesicants, blister agents | Increased PGE2 in BioMAP LPS system (three biomarkers in signature) | RAR/RXR, AhR, VDR receptor classes | Shah et al., 2017 |
| Liver toxicity | Increased incidence of hepatotoxicity, liver steatosis | Amiodarone, tamoxifen, astemizole, ketoconazole, haloperidol, aplaviroc | Decreased SRB in BioMAP 3C system (four biomarkers in signature) | V-ATPase, PiKfyve, phosphorylated | Shahe et al., 2014 |
| Organ toxicity | DNA replication-related organ toxicity | 5-fluorouracil, vincristine, monensin, cisplatin; Classes: chemotherapeutic agents, anti-metabolites, anti-mitotics | Decreased proliferation in BioMAP 3C system (three biomarkers in signature) | DNA replication, microtubules | Berg, 2017 |
| Skin rash (MEK-related) | Increased likelihood of acniform skin rash | Trametinib, AZD6244, p38 MAPK inhibitors, Betsaseron®, anakinra | Increased VCAM-1 in BioMAP HDF3CGF system (two biomarkers in signature) | MEK, p38 MAPK, IL-1R, IL-4R, Tweak receptor, IFNα/β | Keinsteuer et al., 2014a |
| Skin sensitization | Increased potential for allergic skin reactions | NSAIDS, phthalates | Decreased Collagen III in BioMAP HDF3CGF system (two biomarkers in signature) | RAR/RXR, PKC, mitochondrial JNK, prosta glandin receptor | Keinsteuer et al., 2014b |
| Thrombosis | Increased incidence of stroke, deep vein thrombosis, pulmonary embolism | Sirolimus, crizotinib, raloxifene, tamoxifen, clozapine; Classes: polycyclic ary hydrogen carbon, selective estrogen receptor modulators, anti-psychotics | Increased TF/CD142 in BioMAP 3C system (three biomarkers in signature) | mTOR, AhR, V-ATPase, lysosomal function, CYP17A, PKC, NOD2, HIF-1α and receptors for estrogen, histamine H1, thyroid hormone and oncostatin M | Berg et al., 2015 |
| Vascular toxicity | Increased incidence of hypertension, cardiovascular events due to atherosclerosis | Prednisolone, budesonide, panobinostat, trametinib, nicotine | Increased SAA in BioMAP CASM3C system (two biomarkers in signature) | MEK, glucocorticoid and mineral corticoid receptors, HDAC, IL-6R, NAD+/-NADH ratio | Berg, 2017 |
signature by evaluating the full BioMAP Reference Database for all agents exhibiting the signature and determining the level of association of these agents with the clinical AE. Successful signatures were further developed if reference agents were found to be preferentially associated (>90%) with the clinical AE.

Deficiencies in reporting adverse effects do not permit reliable statistical performance metrics for predictive toxicity signatures. Without a statistically rigorous foundation, in order for these signatures to be of practical use, pathway mechanisms driving these signatures are needed. To accomplish this, active reference agents from the database were investigated for their reported mechanisms of action. Target mechanisms specifically enriched in any given reference group were then assigned to the toxicity signature. Following this approach over the past decade, nine human toxicity signatures were developed: acute toxicity, organ toxicity, immunosuppression, liver toxicity, skin rash, irritation, sensitization, thrombosis-related side effects, and vascular inflammation. Table 1 shows the list of signatures, key biomarkers, representative drugs, associated mechanisms and reference publications.

**APPLICATION OF TOXICITY SIGNATURES IN INVESTIGATIVE TOXICOLOGY AND EARLY DISCOVERY**

Predicting the likelihood of drug-induced toxicities in humans is challenging due to known limitations of drug side effect data (Maciejewski et al., 2017). The study from Shah et al. (2017) describes the application of toxicity signatures for investigative toxicology. Researchers at Pfizer previously discovered that a preclinical lead for an mGluR5 program caused skin toxicity in non-human primates, but not in rodents (Zhang et al., 2014). This compound was evaluated in the BioMAP Diversity PLUS® Panel, and analysis of the profile data indicated presence of the BioMAP Toxicity Signature for skin irritation (see Table 1, Definition). Data mining previously associated this signature with activity against the nuclear hormone receptor (NHR) targets, RAR/RXR (agonism), AhR (agonism), or VDR (agonism). Using an orthogonal assay platform (Attagene Factorial® technology, Morrisville NC), the lead compound was confirmed to have activity in functional assays for AhR and VDR, two of the mechanisms previously associated with the skin irritation signature. Additional identified T-cell response biomarker activities supported a proposed hypothesis to explain the observed T cell-mediated type IV hypersensitivity reaction.

This case study illustrates the importance of combining results from multiple platforms to support program advancement. Indeed, the NHR assays highlighted above are not included in standard safety pharmacology panels, as these have not shown sufficient predictivity for safety-related outcomes. Only when combined with the phenotypic profiling results, which provides both tissue context and potential clinical biomarkers, can these assays be useful to a program. Together the results provide sufficient mechanistic rationale to explain why the skin toxicity was not seen in lower animal species and to develop methods for assessing this mechanism in clinical studies.

**DISCUSSION**

Adopting the AOP framework for integrating information from diverse platforms can help drive acceptance of phenotypic assay NAMs by facilitating their incorporation into weight-of-evidence decision strategies. AOPs emphasize the value of information as representative of a key event modality, rather than as an isolated result from a single assay or platform. AOPs can also accommodate other important information for safety de-risking such as in silico models and other in vitro data for predicting pharmacokinetics and ADME properties. These are critical for predicting toxicity effects in vivo and for quantifying safety risks. Indeed, quantitative AOP models represent an active area of research (Perkins et al., 2019; Sallie et al., 2019). Translation of results from animal studies is also facilitated as each of the key mechanistic steps can be evaluated and compared across species. Understanding human/animal differences at the mechanistic level facilitates the selection of appropriate animal models and incorporation of study results into program decisions.

Future research in this area will see advanced complex systems continue to improve and scale. Indeed, new systems for modeling the CNS, kidney, and cancer have been recently described (Petrosyan et al., 2019; Plummer et al., 2019; Trujillo et al., 2019). Key challenges remain, however, particularly in data management and analysis. Assay systems can be complicated requiring significant metadata to describe them effectively. In addition, there has been relatively little standardization around phenotypic data analysis methods. This has made it difficult to compare data across platforms and to make results easily interpreted. Solutions in these areas to standardize analysis methods, incorporate metadata ontologies, and enable data integration, perhaps in conjunction with new methods for data visualization, will be important to facilitate adoption of NAMs. Human-based in vitro methods, and in particular innovative NAMs, have the potential to be especially helpful in reducing safety-related attrition in drug development. They can provide the necessary context at the appropriate pathway, cellular, tissue, or organ level for understanding toxicity mechanisms. Platforms that have sufficient scale and reproducibility to generate large reference databases are particularly useful as they provide a relational connection between targets and clinical outcomes. Anchoring phenotypic NAMs to a mechanistic framework such as those provided by the AOP construct will help with adoption of these approaches, as toxicology moves away from a descriptive science to an evidence-based, mechanistic discipline (Beilmann et al., 2019).

**AUTHOR CONTRIBUTIONS**

EB conceived of and wrote this perspective.
**ACKNOWLEDGMENTS**

The author would like to acknowledge Sheryl P. Denker for significant editorial assistance and Alison O’Mahony and Sharlene Velichko (Eurofins Discovery) for helpful comments.

**REFERENCES**

Bellmann, M., Boonen, H., Czich, A., Dear, G., Hewitt, P., Mow, T., et al. (2019). Optimizing drug discovery by Investigative Toxicology: current and future trends. *ALTEx.* 36, 289–313. doi: 10.14573/altex.1808181

Berg, E. L. (2017). Phenotypic chemical biology for predicting safety and efficacy. *Drug Discov. Today Technol.* 23, 53–60. doi: 10.1016/j.ddtec.2017.01.001

Berg, E. L., Polokoff, M. A., O’Mahony, A., Nguyen, D., and Li, X. (2015). Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems - a chemical biology approach for thrombosis-related side effects. *Int. J. Mol. Sci.* 16, 1008–1029. doi: 10.3390/ijms16101008

Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., et al. (2012). Reducing safety-related drug attrition: the use of *in vitro* pharmacological profiling. *Nat. Rev. Drug Discov.* 11, 909–922. doi: 10.1038/nrd3845

Bray, M. A., Gustafsdottir, S. M., Rohiban, M. H., Singh, S., Ljosa, V., Sokolnicki, K. L., et al. (2017). A dataset of images and morphological profiles of 30 000 small-molecule treatments using the Cell Painting assay. *Gigascience.* 6, 1–9. doi: 10.1093/gigascience/giw014

Brissona, M., Stoitska, A., Fligner, C. L., Revetta, F. L., Washington, M. K., Powers, A. C., et al. (2015). Human islets have fewer blood vessels than mouse islets and the density of islet vascular structures is increased in type 2 diabetes. *J. Histochem. Cytochem.* 63, 637–645. doi: 10.1369/0022155415573324

Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., et al. (2014). Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. *Nat. Rev. Drug Discov.* 13, 419–431. doi: 10.1038/nrd4309

Corthay, A. (2014). Does the immune system naturally protect against cancer? *Front. Immunol.* 5:197. doi: 10.3389/fimmu.2014.00197

Corvi, R., Madia, F., Guyton, K. Z., Kasper, P., Rudel, R., Colacci, A., et al. (2017). Moving forward in carcinogenicity assessment: report of an EU RL ECVAM/ESTIV workshop. *Toxicol. In Vitro.* 45(Pt 3), 278–286. doi: 10.1016/j.tiv.2017.09.010

Dragovic, S., Vermeulen, N. P., Gerets, H. H., Hewitt, P. G., Ingelman-Sundberg, M., Park, B. K., et al. (2016). Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. *Arch. Toxicol.* 90, 2979–3003. doi: 10.1007/s00204-016-1845-1

Edwards, S. W., Tan, Y. M., Villeneuve, D. L., Meek, M. E., and McQueen, C. A. (2016). Adverse outcome pathways-organizing toxicological information to improve decision making. *J. Pharmacol. Exp. Ther.* 356, 170–181. doi: 10.1124/jpet.115.228239

Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., et al. (2013). Recent advances in 2D and 3D *in vitro* systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signalling and ADME. *Arch. Toxicol.* 87, 1315–1330. doi: 10.1007/s00204-013-1078-5

Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., et al. (2016). Screening out irrelevant cell-based models of disease. *Nat. Rev. Drug Discov.* 15, 751–769. doi: 10.1038/nrd.2016.175

Houck, K. A., Dix, D. J., Judson, R. S., Kavlock, R. J., Yang, J., and Berg, E. L. (2009). Profiling bioactivity of the ToxCast chemical library using BioMA primary human cell systems. *J. Biomed. Screen.* 14, 1054–1066. doi: 10.1177/107075109345525

Jang, K. J., Otieno, M. A., Ronxhi, J., Lim, H. K., Ewart, L., Kodella, K. R., et al. (2019). Reproducing human and cross-species drug toxicities using a Liver-Chip. *Sci. Transl. Med.* 11:eaaa5516. doi: 10.1126/scitranslmed.aaa5516

Karbowiak, S. (2011). Scaling of brain metabolism and blood flow in relation to capillary and neural scaling. *PLoS ONE.* 6:e26709. doi: 10.1371/journal.pone.0026709

Kleinstreuer, N., Strickland, J., and Casey, W. (2014b). “Predicting skin sensitization using ToxCast assays,” Abstract #1062C Presented at the Society of Toxicology 53rd Annual Meeting (Phoenix, AZ).

Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., et al. (2014a). Berg bioactivity profiling of a diverse 800 chemical library in human primary cell systems. *Nat. Biotechnol.* 32, 583–591. doi: 10.1038/nbt.2914

Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. *Blood.* 124, 188–195. doi: 10.1182/blood-2014-05-552729

Maciejewski, M., Lounkine, E., Whitebread, S., Farmer, P., DuMouchel, W., Shiochet, B. K., et al. (2017). Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets. *Elife.* 6:e25818. doi: 10.7554/elife.25818

MacRae, S. L., Zhang, Q., Lemetre, C., Seim, I., Calder, R. B., Hoeijmakers, J., et al. (2015). Comparative analysis of genome maintenance genes in naked mole rat, mouse, and human. *Aging Cell.* 14, 288–291. doi: 10.1111/acel.12314

Magdy, T., Schultz, A. J. T., Wu, J. C., Bernstein, D., and Burridge, P. W. (2018). Human induced pluripotent stem cell (hiPSC)-derived cells to assess drug cardiotoxicity: opportunities and problems. *Annu. Rev. Pharmacol. Toxicol.* 58, 83–103. doi: 10.1146/annurev-pharmtox-010617-053110

Mestas, J., and Hughes, C. C. (2004). Of mice and not men: differences between mouse and human immunology. *J. Immunol.* 172, 2731–2738. doi: 10.4049/jimmunol.172.5.2731

Milholland, B., Dong, X., Zhang, L., Hao, X., Suh, Y., and Vijg, J. (2017). Differences between germline and somatic mutation rates in humans and mice. *Nat. Commun.* 8:15183. doi: 10.1038/ncomms15183

Perkins, E. J., Ashauer, B., Burgoon, L., Conolly, R., Landesmann, B., Mackay, C., et al. (2019). Building and applying quantitative adverse outcome pathway models for chemical hazard and risk assessment. *Environ. Toxicol. Chem.* 38, 1850–1865. doi: 10.1002/etc.5405

Petrosyan, A., Cravedi, P., Villani, V., Angeletti, A., Manrique, J., Renieri, A., et al. (2019). A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. *Nat. Commun.* 10:3656. doi: 10.1038/s41467-019-11 577-z

Plummer, S., Wallace, S., Ball, G., Lloyd, R., Schiapparelli, P., Quiñones-Hinojosa, A., et al. (2019). A human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. *Sci. Rep.* 9:1407. doi: 10.1038/s41598-018-38130-0

Salli, K., Frazonosa, J., Baker, N., Ellis-Hutchings, R., Settiuvarsi, R., Carney, E., et al. (2019). Systems modeling of vascular toxicity. *Curr. Op. Toxicol.* 15, 55–63. doi: 10.1016/j.cotox.2019.04.004
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., et al. (2015). Harnessing connectivity in a large-scale small-molecule sensitivity dataset. *Cancer Discov.* 5, 1210–1223. doi: 10.1158/2159-8290.CD-15-0235

Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., et al. (2013). Inflammation and host response to injury, large scale collaborative research program genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc. Natl. Acad. Sci. U.S.A.* 110, 3507–3512. doi: 10.1073/pnas.1222878110

Shah, F., Berg, E., Polokoff, M., Yang, J., and Greene, N. (2014). “Understanding mechanisms of drug-induced liver injury using primary human cell and coculture systems,” Abstract #1647 Presented at the Society of Toxicology 53rd Annual Meeting (Phoenix, AZ).

Shah, F., Stepan, A. F., O’Mahony, A., Velichko, S., Folias, A., Houle, C., et al. (2017). Understanding the mechanism(s) of skin toxicity associated with metabotropic glutamate receptor 5 negative allosteric modulators using primary human cells. *Cell Chem. Biol.* 24, 858–869. doi: 10.1016/j.chembiol.2017.06.003

Sirenko, O., Parham, F., Dea, S., Sodhi, N., Biesmans, S., Mora-Castilla, S., et al. (2019). Functional and mechanistic neurotoxicity profiling using human iPSC-derived neural 3D cultures. *Toxicol Sci.* 167, 58–76. doi: 10.1093/toxsci/kfy218

Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., et al. (2017). A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. *Cell* 171, 1437–1452.e17. doi: 10.1016/j.cell.2017.10.049

Thomas, R. S., Bahadori, T., Buckley, T. J., Cowden, J., Deisenroth, C., Dionisio, K. L., et al. (2019). The next generation blueprint of computational toxicology at the U.S. Environmental Protection Agency. *Toxicol Sci.* 169, 317–332. doi: 10.1093/toxsci/kfx058

Trujillo, C. A., Gao, R., Negraes, P. D., Gu, J., Buchanan, J., Preisol, S., et al. (2019). Complex oscillatory waves emerging from cortical organoids model early human brain network development. *Cell Stem Cell* 25, 558–569.e7. doi: 10.1016/j.stem.2019.08.002

Zhang, L., Balan, G., Barreiro, G., Boscoe, B. P., Chenard, L. K., Cianfroga, J., et al. (2014). Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. *J. Med. Chem.* 57, 861–877. doi: 10.1021/jm401622k

**Conflict of Interest:** EB is an employee of Eurofins Discovery which provides phenotypic profiling services, some of which are described in the present manuscript, and therefore has a potential conflict of interest to declare.

*Copyright © 2019 Berg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*